Bimatoprost and prostaglandin F2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells

Experimental Eye Research

Volumn 80, Issue 1, 2005, Pages 135-145

  Spada, Clayton S ^a   Krauss, Achim H P ^a   Woodward, David F ^a   Chen, June ^a   Protzman, Charles E ^a   Nieves, Amelia L ^a   Wheeler, Larry A ^a   Scott, David F ^b   Sachs, George ^b  

^a ALLERGAN INC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

17 phenyl prostaglandin F2 ; bimatoprost; calcium signaling; cat iris sphincter; prostaglandin F 2

Indexed keywords

17 PHENYLPROSTAGLANDIN F2 ALPHA; BIMATOPROST; CALCIUM; FP RECEPTOR; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CAT; CELL ISOLATION; CELL STIMULATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; EMBRYO; EMBRYO CELL; EVOKED RESPONSE; FIBROBLAST; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IRIS; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SIGNAL TRANSDUCTION; STIMULATION; TISSUE;

AMIDES; ANIMALS; CALCIUM; CALCIUM SIGNALING; CARBACHOL; CATS; CELLS, CULTURED; CHOLINERGIC AGONISTS; DINOPROST; HUMANS; INTRAOCULAR PRESSURE; IRIS; LIPIDS; MICROSCOPY, CONFOCAL; MUSCLE CONTRACTION;

EID: 12344252822     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2004.08.019     Document Type: Article

References (44)

1. N.G. Bazan, and G. Allan Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids Surv. Ophthalmol. 41 1997 S23 S34
2. B.A. Berglund, D.I. Boring, and A.C. Howlett Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. K.V. Honn S. Nigam L.J. Marnett T.R. Walden Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 1999 Kluwer New York 527 533
3. R.F. Brubaker, E.O. Schoff, C.B. Nau, S.P. Carpenter, C. Kuankuan, and A.M. VanDenburgh Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics Am. J. Ophthalmol. 131 2001 19 24
4. S.H. Burstein, R. Rossetti, B. Yagen, and R.B. Zurier Oxidative metabolism of anandamides Prostaglandins Other Lipid Mediators 61 2000 29 41
5. C.B. Camras, A. Alm, P. Watson, and J. Stjernschantz Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups Ophthalmology 103 1996 1916 1924
6. L.B. Cantor Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management Expert Opin. Investig. Drugs 10 2001 721 731
7. R.A. Coleman Prostanoid receptors. D. Girdlestone The IUPHAR Compendium of Receptor Characterization and Classification 1998 IUPHAR Media London 229 244
8. R.A. Coleman, I. Kennedy, P.P.A. Humphrey, K. Bunce, and P. Lumley Prostanoids and their receptors. J.C. Emmett Comprehensive Medicinal Chemistry Membranes and Receptors vol. 3 1990 Pergamon Oxford, UK 643 714
9. R.A. Coleman, W.L. Smith, and S. Narumiya Seventh international union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol. Rev. 46 1994 205 229
10. 2α on aqueous humor dynamics in cynomolgus monkeys Curr. Eye Res. 6 1987 1035 1044
11. S.S. Davies, W.K. Ju, A.H. Neufeld, D. Abram, S. Chemtob, and L.J. Robert II Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro J. Ocul. Pharmacol. Ther. 19 2003 45 54
12. V. Di Marzo Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiological relevance Biochim. Biophys. Acta 1392 1998 153 175
13. H. DuBiner, D. Cooke, M. Dirks, W.C. Stewart, A.M. VanDenburgh, and C. Felix Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost Surv. Ophthalmol. 45 2001 S353 S360
14. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky Cyclooxygenase in biology and disease Fed. Am. Soc. Exp. Biol. J. 12 1998 1063 1073
15. S.E. Easthope, and C.M. Perry Topical bimatoprost. A review of its use in open-angle glaucoma and ocular hyertension Drugs Aging 19 2002 231 248
16. 2α increases uveoscleral outflow in the cynomolgus monkey Exp. Eye Res. 49 1989 389 402
17. 2α on trabecular outflow facility in cynomolgus monkeys Exp. Eye Res. 51 1990 87 91
18. S. Gandolfi, S.T. Simmons, R. Sturm, K. Chen, and A. VanDenburgh Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension Adv. Ther. 18 2001 110 121
19. 2α by human and rabbit ocular tissue J. Ocul. Pharmacol. Ther. 19 2003 97 103
20. K.R. Kozak, B.C. Crews, J.L. Ray, H.H. Tai, J.D. Morrow, and L.J. Marnett Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo J. Biol. Chem. 276 2001 36993 36998
21. A.H-P. Krauss, M. Wiederholt, A. Sturm, and D.F. Woodward Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle Exp. Eye Res. 64 1997 447 453
22. Y.T. Maddox, P.W. Ramwell, C.S. Shiner, and E.J. Corey Amide and l-amino derivatives of F prostaglandins as prostaglandin antagonists Nature (Lond.) 273 1978 549 552
23. I. Matias, J. Chen, L. De Petrocellis, T. Bisogno, A. Ligresti, F. Fezza, A.H.-P. Krauss, L. Shi, C.E. Protzman, C. Li, Y. Liang, A.L. Nieves, K.M. Kedzie, R.M. Burk, V. Di Marzo, and D.F. Woodward Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism J. Pharmacol. Exp. Ther. 309 2004 1 13
24. K.M. Maxey, J.L. Johnson, and J. LaBreque The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist Surv. Ophthalmol. 47 2002 534 540 (suppl 1)
25. 2α-1-isopropyl ester in the cynomolgus monkey Exp. Eye Res. 48 1989 707 716
26. 2 ethanolamide J. Pharmacol. Exp. Ther. 301 2002 900 907
27. T.K. Schaaf, and H-J. Hess Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogs J. Med. Chem. 22 1979 1340 1346
28. U. Schachtschabel, J.D. Lindsey, and R.N. Weinreb The mechanism of action of prostaglandins on uveoscleral outflow Curr. Opin. Ophthalmol. 11 2000 112 115
29. N.A. Sharif, G.W. Williams, and C.R. Kelly Bimatoprost and its free acid are prostaglandin FP receptor agonists Eur. J. Pharmacol. 432 2001 211 213
30. N.A. Sharif, C.R. Kelly, and J.Y. Crider Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor J. Ocul. Pharmacol. Ther. 18 2002 313 324
31. N.A. Sharif, C.R. Kelly, and J.Y. Crider Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor analogues Invest. Ophthalmol. Vis. Sci. 44 2003 715 721
32. N.A. Sharif, C.R. Kelly, J.Y. Crider, G.W. Williams, and S.X. Xu Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells J. Ocul. Pharmacol. Ther. 19 2003 501 515
33. M. Sherwood, and J. Brandt Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure Surv. Ophthalmol. 45 2001 S361 S368
34. I.A. Sorbera, and J. Castaner Travaprost Drugs Future 17 2000 41 45
35. T. Taniguchi, M.S. Haque, K. Sugiyama, N. Hori, and Y. Kitazawa Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits J. Ocul. Pharmacol. Ther. 12 1996 489 498
36. 2 increases uveoscleral outflow and trabecular outflow facility in the cat Exp. Eye Res. 61 1995 649 657
37. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu. Rev. Pharmacol. Toxicol. 38 1998 97 120
38. A. Weber, J. Ni, K-H.J. Ling, A. Acheampong, D.D-S. Tang-Liu, R. Burk, B.F. Cravatt, and D.F. Woodward Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry J. Lipid Res. 45 2004 757 763
39. R.N. Weinreb, C. Toris, B.T. Gabelt, J.D. Lindsey, and P.L. Kaufman Surv. Ophthalmol. 47 2002 S53 S64
40. D.F. Woodward, J.W. Regan, S. Lake, and A. Ocklind The molecular biology and ocular distribution of prostanoid receptors Surv. Ophthalmol. 41 1997 S15 S21
41. 2( with a hydroxyl or methoxy substituent provides biologically unique compounds Br. J. Pharmacol. 130 2000 1933 1943
42. D.F. Woodward, A.H-P. Krauss, J. Chen, R.K. Lai, C.S. Spada, R.M. Burk, S.W. Andrews, L. Shi, Y. Liang, K.M. Kedzie, R. Chen, D.W. Gil, A. Kharlamb, A. Archeampong, J. Ling, C. Madhu, J. Ni, P. Rix, J. Usansky, H. Usansky, A. Weber, B. Brar, L.A. Wheeler, and L.J. Kaplan The pharmacology of bimatoprost (Lumiganα) Surv. Ophthalmol. 45 2001 S337 S345
43. D.F. Woodward, A.H-P. Krauss, J. Chen, Y. Liang, C. Li, C.E. Protzman, A. Bogardus, R. Chen, K.M. Kedzie, H.A. Krauss, D.W. Gil, A. Kharlamb, L.A. Wheeler, D. Babusis, D. Welty, D.D-S. Tang-Liu, M. Cherukury, S.W. Andrews, R.M. Burk, and M.E. Garst Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024) J. Pharmacol. Exp. Ther. 305 2003 772 785
44. M. Yu, D. Ives, and C.S. Ramesha Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2 J. Biol. Chem. 272 1997 21181 21186